Funding for this research was provided by:
AIDS Healthcare Foundation (N/A)
National Institute of Drug Abuse (T32 DA0233561, T32 DA0233561)
National Institute of Mental Health (R25MH067127, R01MH126768, R25MH067127)
BEAT-HIV Collaboratory, co-funded by NIAID, NIMH, NINDS and NIDA (UM1AI126620)
San Diego Center for AIDS Research (SD CFAR), funded by NIAID (P30AI036214)
Received: 11 March 2022
Accepted: 25 May 2022
First Online: 9 July 2022
: The Charles R. Drew University of Medicine and Science (CDU) and the University of North Carolina at Chapel Hill (UNC-CH) IRBs approved the study. Informed consent was obtained from all individual participants included in this study. All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki.
: Participants provided consent to publish de-identified data.
: K.D. has received funding from Gilead Sciences, Inc. and Merck & Co., Inc. that is not directly related to this study. All other authors declare that they have no competing interests.